Aims-To measure the time between onset of symptoms and intention to treat in patients with anti-neutrophil cytoplasmic antibody (ANCA) associated glomerulonephritis; and to investigate the effect of any delay in diagnosis on disease severity at presentation and outcome. Conclusions-Prolonged delay in diagnosis of ANCA associated glomerulonephritis is associated with an increased risk of end stage renal failure. (7 Clin Pathol 1996;49:942-944) 
Effect of diagnostic delay on disease severity and outcome in glomerulonephritis caused by anti-neutrophil cytoplasmic antibodies D P S S Lal, D J O'Donoghue, M Haeney Abstract Aims-To measure the time between onset of symptoms and intention to treat in patients with anti-neutrophil cytoplasmic antibody (ANCA) associated glomerulonephritis; and to investigate the effect of any delay in diagnosis on disease severity at presentation and outcome. Methods-All ANCA positive patients with biopsy proven glomerulonephritis presenting in the North West Region over a consecutive period of 57 months were identified from the North West Glomerular Disease Registry. Sixty nine patients were identified and notes from 61 were reviewed. Results-The 61 patients had a median diagnostic delay of 92 days. In only 12 patients had an ANCA test been performed prior to the nephrology referral. Thirty three patients had renal failure requiring dialysis within one week of admission and had a shorter delay ( Prior to the introduction of cytotoxic immunosuppressive therapy, median patient survival was five months, with less than 20% of patients surviving after one year and less than 10% after two years.' Immunosuppressive therapy has improved survival: remission can be achieved in over 80% of patients4 and the five year survival rate is now over 70%.5 Despite these advances, many patients with renal involvement still require dialysis at presentation. Furthermore, there has been a suggestion that early treatment can improve renal prognosis further. 6 Our aim was to see whether diagnostic delay increases the severity of disease presentation and influences long term outcome. 
Methods

Discussion
The spectrum of ANCA associated disease includes patients with limited renal disease, microscopic polyarteritis, leucocytoclastic angiitis, Wegener's granulomatosis, and the Churg Strauss syndrome.' When the kidney is involved in an ANCA associated vasculitis, variously reported in 18-100% of cases, the most common histological lesion is pauciimmune focal segmental glomerular necrosis with crescent formation and only mild hypercellularity.2
From the clinical viewpoint, ANCA associated glomerulonephritis presents in two broad ways: either as a rapidly progressive glomerulonephritis presenting as a medical emergency or a more indolent course of progressive renal impairment.9 As ANCA associated glomerulonephritis now constitutes the most common cause of rapidly progressive glomerulonephritis,1°it would be expected that an ANCA assay would have been performed in all such cases prior to renal referral. However, although the ANCA assay has been available for over 10 years," we found that the test had been performed in only 12 of 61 patients.
Our findings confirm that two disease patterns exist within the spectrum of ANCA associated glomerulonephritis: those needing dialysis have a rapidly progressive course, whereas those in the dialysis independent group have a more indolent condition. Because dialysis usually requires transfer to a renal centre, the delay in diagnosing ANCA associated disease is shorter than in those not requiring dialysis. Furthermore, in those requiring dialysis, recovery was associated with shorter diagnostic delay. A longer delay was associated with an increased number of obsolescent glomeruli at presentation and an increased risk of end stage renal failure at final follow up.
We conclude that delay in diagnosing and treating patients with ANCA associated glomerulonephritis has an adverse effect on outcome. This holds true both for patients pre 
